Solventum (SOLV) Stock Forecast & Price Target

$72.95

+0.82 (+1.14%)

(As of 02:46 PM ET)

Solventum - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce
Based on 7 Analyst Ratings

Based on 7 Wall Street analysts who have issued ratings for Solventum in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 7 analysts, 1 has given a sell rating, and 6 have given a hold rating for SOLV.

Consensus Price Target

$58.25
-20.15% Downside

High Forecast	$64.00
Average Forecast	$58.25
Low Forecast	$54.00

According to the 7 analysts' twelve-month price targets for Solventum, the average price target is $58.25. The highest price target for SOLV is $64.00, while the lowest price target for SOLV is $54.00. The average price target represents a forecasted downside of -20.15% from the current price of $72.95.

Type	Current Forecast 9/20/23 to 9/19/24	1 Month Ago 8/21/23 to 8/20/24	3 Months Ago 6/22/23 to 6/21/24	1 Year Ago 9/20/22 to 9/20/23
Consensus Rating	Reduce	Reduce	Reduce	N/A
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	N/A
Buy	0 Buy rating(s)	0 Buy rating(s)	0 Buy rating(s)	N/A
Hold	6 Hold rating(s)	5 Hold rating(s)	4 Hold rating(s)	N/A
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	N/A
Consensus Price Target	$58.25	$58.25	$65.75	N/A
Forecasted Upside	-20.15% Downside	6.97% Upside	1.10% Upside	N/A

Trump Warns Gov. Can Confiscate Your Money. CBDC's give Gov. absolute (Ad)

Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.

This means you must act NOW before it's too late.

SOLV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SOLV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Solventum Stock vs. The Competition

Type	Solventum	Medical Companies	S&P 500
Consensus Rating Score	1.86	2.77	2.50
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	-19.24% Downside	1,006.89% Upside	7.94% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/5/2024	BTIG Research 2 of 5 stars	R. Zimmerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral
8/12/2024	The Goldman Sachs Group 2 of 5 stars		Boost Target	Sell ➝ Sell	$48.00 ➝ $54.00	-6.56%
8/9/2024	Wells Fargo & Company 3 of 5 stars		Lower Target	Equal Weight ➝ Equal Weight	$69.00 ➝ $64.00	+5.66%
7/15/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$70.00 ➝ $55.00	+13.90%
6/25/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$70.00 ➝ $60.00	+17.26%
6/24/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold
4/2/2024	Edward Jones Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:06 PM ET.

SOLV Forecast - Frequently Asked Questions

What is Solventum's forecast for 2024?: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Solventum is $58.25, with a high forecast of $64.00 and a low forecast of $54.00.
Should I buy or sell Solventum stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Solventum in the last year. There is currently 1 sell rating and 6 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" SOLV shares.
Does Solventum's stock price have much upside?: According to analysts, Solventum's stock has a predicted upside of 6.97% based on their 12-month stock forecasts.
What analysts cover Solventum?: Solventum has been rated by research analysts at Argus, Bank of America, BTIG Research, Morgan Stanley, The Goldman Sachs Group, and Wells Fargo & Company in the past 90 days.
Do Wall Street analysts like Solventum more than its competitors?: Analysts like Solventum less than other "medical" companies. The consensus rating for Solventum is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SOLV compares to other companies.